Enlivex Therapeutics (ENLV) 6-K/A 13 Oct 20 2020 Q2 Condensed Consolidated Financial Statements Financial data

Document And Entity Information

Document And Entity Information	6 Months Ended
	Jun. 30, 2020
Document Information Line Items
Entity Registrant Name	Enlivex Therapeutics Ltd.
Document Type	6-K/A
Current Fiscal Year End Date	--12-31
Amendment Flag	true
Amendment Description	This Amendment to the Report on Form 6-K for the month of August 2020, originally by Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (“Enlivex”), with the Securities and Exchange Commission on August 14, 2020 (the “Form 6-K”), is being filed solely for the purposes of furnishing the Interactive Data File disclosure as Exhibit 101 in accordance with Rule 405 of Regulation S-T. Other than as expressly set forth above, this Report on Form 6-K/A does not, and does not purport to, amend, update or restate the information in any other item of the Form 6-K, or reflect any events that have occurred after the Form 6-K was originally filed. This Report on Form 6-K/A, including the exhibit hereto, is incorporated by reference into Enlivex’s registration statements on Form F-3 (File No. 333-232413 and File No. 333-232009) filed with the Securities and Exchange Commission.
Entity Central Index Key	0001596812
Document Period End Date	Jun. 30, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q2
Entity File Number	001-36578

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 10,163	$ 3,948
Short term deposits	20,043	8,060
Prepaid expenses	708	510
Other receivables	751	403
Restricted cash	145	100
Cash held with respect to CVR Agreement	2,524	1,400
Receivables for the sale of Trehalose		2,000
Total Current Assets	34,334	16,421
Non-Current Assets
Restricted cash	60	76
Long-term prepaid expenses	5	5
Property and equipment, net	696	648
Other assets	342	410
Total Non-Current Assets	1,103	1,139
TOTAL ASSETS	35,437	17,560
Current Liabilities
Accounts payable trade	524	395
Accrued expenses and other liabilities	1,961	2,185
CVR holders	2,524	3,400
Total Current Liabilities	5,009	5,980
Non-Current Liabilities
Lease liabilities	236	298
Total Non-Current Liabilities	236	298
TOTAL LIABILITIES	5,245	6,278
SHAREHOLDERS’ EQUITY
Authorized: 45,000,000 shares as of June 30, 2020 and December 31, 2019; Issued and outstanding: 13,463,771 and 10,334,126 as of June 30, 2020 and December 31, 2019;	1,513	1,151
Additional paid in capital	59,615	37,104
Foreign currency translation adjustments	(1,428)	(1,300)
Accumulated deficit	(29,508)	(25,673)
TOTAL SHAREHOLDERS’ EQUITY	30,192	11,282
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 35,437	$ 17,560

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)	Jun. 30, 2020$ / sharesshares	Jun. 30, 2020₪ / sharesshares	Dec. 31, 2019$ / sharesshares	Dec. 31, 2019₪ / sharesshares
Statement of Financial Position [Abstract]
Common stock, par value (in Dollars per share) | (per share)	$ 0.11	₪ 0.40	$ 0.11	₪ 0.40
Common stock, shares authorized	45,000,000	45,000,000	45,000,000	45,000,000
Common stock, shares issued	13,463,771	13,463,771	13,463,771	13,463,771
Common stock, shares outstanding	10,334,126	10,334,126	10,334,126	10,334,126
Common stock, par value (in New Shekels per share) | (per share)	$ 0.11	₪ 0.40	$ 0.11	₪ 0.40

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Operations And Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Revenues
Research and development expenses	1,360	696	2,732	2,274
General and administrative expenses	873	601	1,397	1,385
Total operating expenses	2,233	1,297	4,129	3,659
Operating loss	(2,233)	(1,297)	(4,129)	(3,659)
Financial income	89	38	298	93
Financial expenses	(897)	(202)	(4)	(560)
Net (loss)	(3,041)	(1,461)	(3,835)	(4,126)
Exchange differences arising from translating financial statements from functional to presentation currency	888	234	(128)	534
Total other comprehensive income (loss)	888	234	(128)	534
Total comprehensive (loss)	$ (2,153)	$ (1,227)	$ (3,963)	$ (3,592)
Basic & diluted (loss) per share (in Dollars per share)	$ (0.23)	$ (0.14)	$ (0.31)	$ (0.62)
Weighted average number of shares outstanding (in Shares)	13,441,436	10,108,265	12,419,643	7,021,027

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net (loss)	$ (3,835)	$ (4,126)
Depreciation	114	95
Non-cash operating lease expenses	66	67
Share-based compensation	320	643
Changes in values of warrants exercisable into shares liability		50
Decrease (increase) in prepaid expenses	(196)	41
Decrease (increase) in other receivables	1,640	(359)
(Decrease) increase in accounts payable trade	129	127
(Decrease) increase in accrued expenses and other liabilities	(1,071)	199
Operating lease liabilities	(62)	(81)
Net cash provided by (used in) operating activities	(2,895)	(3,344)
Cash flows from investing activities
Purchase of property and equipment	(166)	(132)
Investment in short-term bank deposits	(12,000)
Net cash received in the issuance of shares for the net assets of Bioblast Pharma Ltd.		1,544
Net cash (used in) provided by investing activities	(12,166)	1,412
Cash flows from financing activities
Proceeds from issuance of shares and warrants net of $2,294 and $655 issuance expenses, respectively	22,456	7,706
Proceeds from exercise of options	97	4
Net cash (used in) provided by financing activities	22,553	7,710
Increase (decrease) in cash and cash equivalents	7,492	5,778
Cash and cash equivalents - beginning of year	5,524	9,792
Exchange rate differences on cash and cash equivalents	(124)	535
Cash and cash equivalents - end of period	12,892	16,105
Non-cash transactions:
Warrants issued in settlement of issuance costs to a placement agent	563
Conversion of preferred stock to ordinary shares		525
Conversion of 6% preference on preferred stock to ordinary shares		2,071
Issuance of ordinary shares upon exercise of warrants		249
Issuance of shares in connection with merger		47
Assets acquired excluding cash and cash equivalents		(2,632)
Less - liabilities assumed		3,532
Net assets acquired excluding cash and cash equivalents		900
Supplemental disclosures of cash flow information:
Cash paid for taxes
Cash received for interest, net	$ 72	$ 93

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Statement of Cash Flows [Abstract]
warrants net issuance expenses	$ 2,294	$ 655

General

General	6 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL a. Enlivex Therapeutics Ltd. (the “Parent” and, including its consolidated subsidiaries, “we”, “us”, “our” or the “Company”) is a clinical-stage immunotherapy company originally incorporated on January 22, 2012 under the laws of the State of Israel as Bioblast Pharma Ltd. On March 26, 2019, upon consummation of a merger transaction between the Parent and Enlivex Therapeutics R&D Ltd., (“Enlivex R&D”, formerly known as Enlivex Therapeutics Ltd.), pursuant to which a wholly owned subsidiary of the Parent merged with and into Enlivex R&D (the “ Merger Enlivex R&D was incorporated in September 2005 under the laws of the State of Israel and has been engaged since inception in the development of an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions, which involve the hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no U.S. Food and Drug Administration (“ FDA In January 2015, Bioblast Pharma Inc. was established in the State of Delaware as a wholly owned subsidiary of the Parent (the “Subsidiary”). On July 1, 2020 Bioblast Pharma Inc changed its name to Enlivex Therapeutics Inc. The Company’s ordinary shares, NIS 0.40 per share (“Ordinary Shares” or “ordinary shares”), are traded under the symbol “ENLV” on both the Nasdaq Capital Market and on the on the Tel Aviv Stock Exchange. b. Financial Resources The Company devotes substantially all of its efforts toward research and development activities and raising capital. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. Research and development activities have required significant capital investment since the Company’s inception. The Company expects its operations to continue to require cash investment to pursue the Company’s research and development activities, including preclinical studies, formulation development, clinical trials and related drug manufacturing. The Company has not generated any revenues or product sales and has not achieved profitable operations or positive cash flow from operations. The Company’s has experienced losses since its inception, and, as of June 30, 2020, had an accumulated deficit of $29,508. In the first quarter of 2020, the Company raised $24,750 in cash (before deducting placement agent fees and offering expenses) in conjunction with registered securities offerings of an aggregate of 3,093,750 Ordinary Shares and 2,093,750 warrants. However, the Company expects to continue to incur additional losses for at least the next several years and over that period the Company will need to raise additional debt or equity financing or enter into partnerships to fund its development. If the Company is not able to achieve its funding requirements, it may be required to reduce discretionary spending, may not be able to continue the development of its product candidates or may be required to delay part of its development programs, which could have a material adverse effect on the Company’s ability to achieve its intended business objectives. There can be no assurances that additional financing will be secured or, if secured, will be on favorable terms. The ability of the Company to transition to profitability in the longer term is dependent on developing products and product revenues to support its expenses. The Company’s management and board of directors are of the opinion that its current financial resources will be sufficient to continue the development of the Company’s product candidates for at least twelve months from the filing of these financial statements on Form 6-K with no additional need to raise capital. The Company may determine, however, to raise additional capital during such period as its Board of Directors deems prudent The Company’s management plans to finance the Company’s operations with issuances of its equity securities and, in the longer term, revenues. There are no assurances, however, that the Company will be successful in obtaining an adequate level of financing needed for its long-term development. The Company’s ability to continue to operate in the long term is dependent upon additional financial support. . In addition to the foregoing, based on the Company’s current assessment, the Company does not expect any material impact on its development timeline or its liquidity due to currently ongoing COVID-19 pandemic. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, will depend on future developments that are highly uncertain as of the date of issuance of these unaudited condensed consolidated financial statements. Actual results could differ from the Company’s estimates.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES a. Basis of Presentation These unaudited consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements for annual periods prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2019 Annual Report on Form 20-F, as filed with the SEC on April 30, 2020. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2019 financial information has been derived from the Company’s audited financial statements. b. Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the New Israeli Shekel (“NIS”), which is the local currency in which it operates. The financial statements of the Company were translated into U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Accordingly, assets and liabilities were translated from NIS to U.S. dollars using period -end exchange rates, equity items were translated at the exchange rates of the date of the equity transaction, and income and expense items were translated at average exchange rates during the period . Gains or losses resulting from translation adjustments (which result from translating an entity’s financial statements into U.S. dollars if its functional currency is other than the U.S. dollar) are reported in other comprehensive income (loss) and are reflected in equity, under “accumulated other comprehensive income (loss)”. Balances denominated in, or linked to foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of income, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. 1 U.S. $ = 3.466 NIS and 3.456 NIS as of June 30, 2020 and December 31, 2019, respectively. The U.S. $ (decreased) increased against the NIS (2.8%) and (1.85%) in the three months ended June 30, 2020 and 2019, respectively, and 0.29% and (4.88%) in the six months ended June 30, 2020 and 2019, respectively. c. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations. d. New Accounting Pronouncements Adopted In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, “Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial statements. In August 2018, the FASB issued new disclosure guidance on fair value measurement. This new guidance modifies the disclosure requirements on fair value measurements, including removal and modifications of various current disclosures as well as some additional disclosure requirements for Level 3 fair value measurements. Some of these disclosure changes must be applied prospectively while others retrospectively depending on requirement. This guidance is required to be adopted by the Company beginning in fiscal year 2020 with early adoption permitted. The Company adopted the guidance on January 1, 2020, which did not have a material impact on its consolidated financial statements. e. Pending Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting due to reference rate reform. The guidance in this update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures, the adoption of this ASU is not expected to have a material impact on its consolidated financial statements.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash	6 Months Ended
	Jun. 30, 2020
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND RESTRICTED CASH	NOTE 3 – CASH, CASH EQUIVALENTS AND RESTRICTED CASH June 30, December 31, 2020 2019 unaudited Cash held in banks $ 655 $ 937 Bank deposits in U.S.$ (annual average interest rates 1.26% and 1.49%) 9,508 3,011 Total cash and cash equivalents 10,163 3,948 Cash held with respect to CVR Agreement 2,524 1,400 Short-term restricted cash 145 100 Long-term restricted cash 60 76 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 12,892 $ 5,524

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 PROPERTY AND EQUIPMENT Property and equipment, net consists of the following: June 30, December 31, 2020 2019 unaudited Cost: Laboratory equipment $ 917 $ 782 Computers 113 94 Office furniture & equipment 37 36 Leasehold improvements 164 152 Total cost 1,231 1,064 Accumulated depreciation: Laboratory equipment 433 340 Computers 63 51 Office furniture & equipment 2 1 Leasehold improvements 37 24 Total accumulated depreciation 535 416 Depreciated cost $ 696 $ 648 For the three and six months ended June 30, 2020 and 2019, depreciation expenses were $60, $92, $114 and $95, respectively.

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 ACCRUED EXPENSES AND OTHER LIABILITIES June 30, December 31, 2020 2019 unaudited Vacation, convalescence and bonus accruals $ 253 $ 318 Employees and payroll related 265 274 Short term operating lease liabilities 123 123 Accrued expenses and other 1,320 1,470 $ 1,961 $ 2,185

Leases

Leases	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
LEASES	NOTE 6 LEASES The Company is a party to operating leases for its corporate offices, laboratory space and vehicles. The Company’s operating leases have remaining lease terms of up to 3.16 years, some of which include options to extend the leases for up to five years. June 30, 2020 2019 unaudited The components of lease expense were as follows: Operating leases expenses $ 93 $ 98 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 88 $ 93 Non-cash activity: $ - $ - Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows: June 30, December 31, 2020 2019 unaudited Other assets - Right-of-Use assets $ 500 $ 501 Accumulated amortization 158 91 Operating lease Right-of-Use assets, net $ 342 $ 410 Lease liabilities – current - Accounts payable and accrued liabilities $ 123 $ 123 Lease liabilities – noncurrent 236 298 Total operating lease liabilities $ 359 $ 421 Weighted average remaining lease term in years 2.83 3.33 Weighted average annual discount rate 10.7 % 10.7 % Maturities of operating lease liabilities as of June 30, 2020, were as follows: 2020 (after June 30) 83 2021 154 2022 135 2023 73 Total undiscounted lease liability 445 Less: Imputed interest (86 ) Present value of lease liabilities $ 359

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 7 COMMITMENTS AND CONTINGENCIES a. The Company is required to pay royalties to the State of Israel (represented by the Israel Innovation Authority), computed on the basis of proceeds from the sale or license of products, the development of which was supported by State grants. These royalties are generally 3% - 5% of sales until repayment of 100% of the grants (linked to the U.S. dollar) received by the Company plus annual interest at an applicable LIBOR-based rate. The Company’s aggregate contingent obligation to pay royalties as of June 30, 2020 was approximately $5,804, which represented the gross amount of grants actually received by the Company from the Israel Innovation Authority to such date, including accrued interest. As of June 30, 2020, the Company had not paid any royalties to the Israel Innovation Authority. In January 2020, the Company submitted a grant application to the Israel Innovation Authority for funding of its clinical development program of prevention of cytokine storms and organ dysfunction associated with sepsis. The Company’s application for grants of NIS 3,467 ($973) representing participation of 30% of the plan to be executed in Israel was approved by the Israel Innovation Authority in April 2020, for a period commencing January 1, 2020 and ending December 31, 2020. In March 2020, the Company submitted a grant application to the Israel Innovation Authority for funding of its clinical development program of prevention of organ dysfunction and cytokine storms associated with COVID-19. The Company’s application for grants of NIS 1,857 ($521) representing participation of 30% of the plan to be executed in Israel was approved by the Israel Innovation Authority in April 2020 for a period commencing April 1, 2020 and ending March 31, 2021. b. On July 1, 2020 the Company entered into a rental agreement for an additional 421 square meters of office and laboratory space, in addition to the 420 square meter rental agreement entered into on July 30, 2018, in the biotechnology park in Ness Ziona. The additional rental agreement is for a period of 63 months, commencing July 1, 2020, and can be extended by an additional period of 35 months. The monthly rental and management fees for the additional space are NIS 28 ($8). To secure the liability of the Company for the new lease, the Company provided the lessor a bank guarantee of approximately NIS 164 ($47). On May 15, 2020, S.H.N. Financial Investments Ltd., d/b/a Shamir Capital (“Shamir”) filed a complaint against the Company in the United States District Court for the Southern District of New York (the “Court”), related to Shamir’s purchase of $2.4 million of ordinary shares in the Company’s registered direct offering in February 2020. The Company considered Shamir’s allegations to be without merit, and, on July 20, 2020, filed with the Court a motion to dismiss Shamir’s complaint. On August 10, 2020, without challenging the Company’s motion to dismiss and prior to the Company filing an answer to Shamir’s complaint, Shamir filed with the Court a notice of voluntary dismissal without prejudice.

Equity

Equity	6 Months Ended
	Jun. 30, 2020
Equity [Abstract]
EQUITY	NOTE 8 EQUITY a. On February 26, 2020, the Company completed a registered offering of ordinary shares pursuant to which certain investors purchased 1,000,000 ordinary shares at a price of $8 per share. Net proceeds of the offering were approximately $7,218 after deducting offering expenses. In conjunction with the offering, the Company issued to the placement agent warrants to purchase up to 70,000 ordinary shares at an exercise price of $10 per share , b. On March 5, 2020, the Company completed a registered offering pursuant to which certain investors purchased 2,093,750 ordinary shares and 2,093,750 warrants to purchase ordinary shares at a combined offering price of $8.00 per ordinary share and associated warrant. Net proceeds of the offering were approximately $15,238 after deducting offering expenses. The investors’ warrants are immediately exercisable for 2,093,750 ordinary shares of common stock at $9 per share, and will remain exercisable until the two-year anniversary of their date of issuance. The sale of ordinary shares and issuance of warrants qualified for equity treatment under GAAP. The respective values of the warrants and ordinary shares issued to investors were calculated using their relative fair values and classified under ordinary shares and additional paid-in capital. The warrants were valued using a Black-Scholes model with the following assumptions: estimated weighted average volatility 68.24%; weighted average risk-free interest rate of 0.67%; no dividend; and a weighted average contractual expected life of 2 years. The value ascribed to the investors’ warrants was $3,723 and to the common stock $13,027. In conjunction with the offerings, the Company also issued to the placement agent warrants to purchase up to 146,563 ordinary shares at an exercise price of $10 per share, such warrants have substantially the same terms as the investor warrants, except that the placement agent warrants are exercisable at a price of $10 per share. The placement agent warrants were valued at $232 using a Black-Scholes model with the same assumptions used to estimate the investors’ warrants. The placement agent warrants were accounted for as additional issuance costs and classified under additional paid-in capital. c. All warrants issued in February and March 2020 offerings described above may be exercisable on a “cashless” basis in certain circumstances, including while there is no effective registration statement registering the ordinary shares issuable upon exercise of the warrants until the expiry of the warrants. Such registration statement was declared effective by the SEC on June 21, 2019. Holders of the Company’s warrants have no rights as an ordinary shareholder until such holders exercise their warrants and acquire the Company’s ordinary shares. All of the foregoing warrants remained outstanding at June 30, 2020.

Share-Based Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
SHARE-BASED COMPENSATION	NOTE 9 – SHARE-BASED COMPENSATION a) Employees’ and directors stock options Three months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 1,195,563 $ 6.30 1,097,943 $ 6.01 Granted 250,000 $ 3.66 - $ - Forfeited and expired (31,070 ) $ 6.36 (6,292 ) $ 7.23 Exercised (35,895 ) $ 2.69 - $ - Outstanding at end of period 1,378,598 $ 6.15 1,091,651 $ 6.01 Exercisable at end of period 692,032 $ 5.96 553,331 $ 6.03 Non-vested at beginning of the period 482,010 $ 7.20 544,612 $ 6.02 Granted 250,000 $ 3.66 - $ - Vested during the year (14,374 ) $ 3.63 - $ - Forfeited during the year (31,070 ) $ 6.38 (6,292 ) $ 7.23 Non-vested at the end of the period 686,566 $ 5.79 538,320 $ 6.08 Six months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 1,125,927 $ 6.47 1,083,023 $ 4.79 Pre-merger Bioblast options - $ - 15,500 $ 90.16 Granted 320,000 $ 3.89 2,421 $ 12.21 Forfeited and expired (31,434 ) $ 6.39 (8,071 ) $ 0.91 Exercised (35,895 ) $ 2.69 (1,222 ) $ 3.39 Outstanding at end of period 1,378,598 $ 6.15 1,091,651 $ 6.01 Exercisable at end of period 692,032 $ 5.96 553,331 $ 6.03 Non-vested at beginning of the period 425,895 $ 7.21 625,302 $ 5.58 Granted 320,000 $ 3.89 2,421 $ 12.21 Vested during the year (28,259 ) $ 3.09 (81,332 ) $ 3.22 Forfeited during the year (31,070 ) $ 6.37 (8,071 ) $ 0.91 Non-vested at the end of the period 686,566 $ 5.79 538,320 $ 6.08 As of June 30, 2020, the total unrecognized estimated compensation cost related to outstanding non-vested employees’ stock options was $1,750 which is expected to be recognized over a weighted average period of 1.51 years. b) Consultants’ stock options Three months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 499,115 $ 4.04 718,395 $ 3.72 Outstanding at end of period 499,115 $ 4.04 718,395 $ 3.72 Exercisable at end of period 405,920 $ 3.48 576,183 $ 5.26 Non-vested at beginning of the period 93,194 $ 6.27 142,212 $ 6.29 Vested during the year - $ - - $ - Non-vested at the end of the period 93,194 $ 6.27 142,212 $ 6.29 Six months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 499,115 $ 4.04 718,395 $ 3.72 Outstanding at end of period 499,115 $ 4.04 718,395 $ 3.72 Exercisable at end of period 405,920 $ 3.48 576,183 $ 5.26 Non-vested at beginning of the period 100,456 $ 6.27 149,474 $ 6.20 Vested during the year (7,262 ) $ 6.22 (7,262 ) $ 6.22 Non-vested at the end of the period 93,194 $ 6.27 142,212 $ 6.29 As of June 30, 2020, the unrecognized estimated compensation cost related to outstanding non-vested consultants’ stock options was $199 which is expected to be recognized over a weighted average period of 1.44 years. c) Set forth below is additional data for all options outstanding at June 30, 2020: Exercise price Number of options outstanding Remaining contractual Life (in years) Intrinsic Value of Options Outstanding No. of options exercisable $ 2.69 688,026 5.02 1,630,623 686,720 $ 3.66 250,000 9.84 349,250 13,889 $ 4.68 66,500 9.76 25,270 - $ 6.22 687,303 7.55 - 377,329 $ 8.19 150,000 9.39 - - $ 10.12 12,943 8.43 - 3,909 $ 12.21 2,421 8.75 - 605 $ 21.40 5,020 9.07 - - $ 90.16 15,500 1.19 - 15,500 1,877,713 $ 2,005,143 1,097,952 d) The following table summarizes share-based compensation expenses related to grants under the Equity Incentive Plans included in the statements of operations: Three months ended Six months ended 2020 2019 2020 2019 Research & development $ 104 $ 31 $ 200 $ 444 General & administrative 84 100 120 199 Total $ 188 $ 131 $ 320 $ 643

Transactions with Related Parti

Transactions with Related Parties	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
TRANSACTIONS WITH RELATED PARTIES	NOTE 10 TRANSACTIONS WITH RELATED PARTIES On May 12, 2019, the Company entered into a research agreement with Cell Generation (C-G) Ltd, a company controlled by its Chief Scientific & Medical Officer under which Cell Generation (C-G) Ltd undertook to perform a patients' study. a) Amounts due to the related party June 30, December 31, 2020 2019 unaudited Accounts payable trade $ 68 $ - Accrued expenses and other 65 79 $ 133 $ 79 b) Amount of transaction with the related party Three months ended Six months ended 2020 2019 2020 2019 Research and development services $ 160 $ - $ 444 $ -

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	NOTE 11 – FAIR VALUE MEASUREMENT The Company’s financial assets and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of June 30, 2020 and December 31, 2019: June 30, 2020 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 10,163 $ 10,308 $ - $ - Short term deposits 20,043 20,043 - - Cash held with respect to CVR Agreement 2,524 2,524 - - Restricted cash 205 205 - - Total financial assets $ 32,935 $ 32,935 $ - $ - December 31, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,948 $ 3,948 $ - $ - Short term deposits 8,060 8,060 - - Cash held with respect to CVR Agreement 1,400 1,400 - - Restricted cash 176 176 - - Total financial assets $ 13,584 $ 13,584 $ - $ -

Events Subsequent to the Balanc

Events Subsequent to the Balance Sheet Date	6 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE	NOTE 12 – EVENTS SUBSEQUENT TO THE BALANCE SHEET DATE The Company evaluated all events and transactions that occurred subsequent to the balance sheet date and prior to the date on which these financial statements were issued, and determined that the following events necessitated disclosure: On July 1, 2020 the Company’s U.S. subsidiary Bioblast Pharma Inc. changed its name to Enlivex Therapeutics Inc. Additionally, on August 10, 2020, Shamir voluntarily dismissed its complaint against the Company. See Note 7.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation These unaudited consolidated financial statements include the accounts of the Company and have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information. Accordingly, certain information and footnote disclosures normally included in financial statements for annual periods prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited annual financial statements and notes thereto included in the Company’s 2019 Annual Report on Form 20-F, as filed with the SEC on April 30, 2020. The results of operations for these interim periods are not necessarily indicative of the operating results for any future period. The December 31, 2019 financial information has been derived from the Company’s audited financial statements.
Functional Currency and Translation to The Reporting Currency	b. Functional Currency and Translation to The Reporting Currency The functional currency of the Company is the New Israeli Shekel (“NIS”), which is the local currency in which it operates. The financial statements of the Company were translated into U.S. dollars in accordance with ASC 830, “Foreign Currency Matters”. Accordingly, assets and liabilities were translated from NIS to U.S. dollars using period -end exchange rates, equity items were translated at the exchange rates of the date of the equity transaction, and income and expense items were translated at average exchange rates during the period . Gains or losses resulting from translation adjustments (which result from translating an entity’s financial statements into U.S. dollars if its functional currency is other than the U.S. dollar) are reported in other comprehensive income (loss) and are reflected in equity, under “accumulated other comprehensive income (loss)”. Balances denominated in, or linked to foreign currencies are stated on the basis of the exchange rates prevailing at the balance sheet date. For foreign currency transactions included in the statement of income, the exchange rates applicable on the relevant transaction dates are used. Transaction gains or losses arising from changes in the exchange rates used in the translation of such balances are carried to financing income or expenses as applicable. 1 U.S. $ = 3.466 NIS and 3.456 NIS as of June 30, 2020 and December 31, 2019, respectively. The U.S. $ (decreased) increased against the NIS (2.8%) and (1.85%) in the three months ended June 30, 2020 and 2019, respectively, and 0.29% and (4.88%) in the six months ended June 30, 2020 and 2019, respectively.
Reclassification of Prior Year Presentation	c. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
New Accounting Pronouncements Adopted	d. New Accounting Pronouncements Adopted In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, “Fair Value Measurement (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement,” which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with the movement amongst or hierarchy associated with Level 1, Level 2 and Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this ASU on January 1, 2020. The adoption of this ASU did not have a material impact on its consolidated financial statements. In August 2018, the FASB issued new disclosure guidance on fair value measurement. This new guidance modifies the disclosure requirements on fair value measurements, including removal and modifications of various current disclosures as well as some additional disclosure requirements for Level 3 fair value measurements. Some of these disclosure changes must be applied prospectively while others retrospectively depending on requirement. This guidance is required to be adopted by the Company beginning in fiscal year 2020 with early adoption permitted. The Company adopted the guidance on January 1, 2020, which did not have a material impact on its consolidated financial statements.
Pending Accounting Pronouncements	e. Pending Accounting Pronouncements In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (Topic 848), which provides optional guidance to ease the potential burden in accounting due to reference rate reform. The guidance in this update provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into on or before December 31, 2022. The adoption of this ASU is not expected to have a material impact on the Company’s consolidated financial statements. In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures, the adoption of this ASU is not expected to have a material impact on its consolidated financial statements.

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash (Tables)	6 Months Ended
	Jun. 30, 2020
Cash and Cash Equivalents [Abstract]
Schedule of cash and cash equivalents and restricted cash	June 30, December 31, 2020 2019 unaudited Cash held in banks $ 655 $ 937 Bank deposits in U.S.$ (annual average interest rates 1.26% and 1.49%) 9,508 3,011 Total cash and cash equivalents 10,163 3,948 Cash held with respect to CVR Agreement 2,524 1,400 Short-term restricted cash 145 100 Long-term restricted cash 60 76 Total cash, cash equivalents and restricted cash shown in the statement of cash flows $ 12,892 $ 5,524

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	June 30, December 31, 2020 2019 unaudited Cost: Laboratory equipment $ 917 $ 782 Computers 113 94 Office furniture & equipment 37 36 Leasehold improvements 164 152 Total cost 1,231 1,064 Accumulated depreciation: Laboratory equipment 433 340 Computers 63 51 Office furniture & equipment 2 1 Leasehold improvements 37 24 Total accumulated depreciation 535 416 Depreciated cost $ 696 $ 648

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2020
Payables and Accruals [Abstract]
Schedule of accrued expenses and other liabilities	June 30, December 31, 2020 2019 unaudited Vacation, convalescence and bonus accruals $ 253 $ 318 Employees and payroll related 265 274 Short term operating lease liabilities 123 123 Accrued expenses and other 1,320 1,470 $ 1,961 $ 2,185

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of operating lease	June 30, 2020 2019 unaudited The components of lease expense were as follows: Operating leases expenses $ 93 $ 98 Supplemental consolidated cash flow information related to operating leases follows: Cash used in operating activities $ 88 $ 93 Non-cash activity: $ - $ -
Schedule of operating lease related activities	June 30, December 31, 2020 2019 unaudited Other assets - Right-of-Use assets $ 500 $ 501 Accumulated amortization 158 91 Operating lease Right-of-Use assets, net $ 342 $ 410 Lease liabilities – current - Accounts payable and accrued liabilities $ 123 $ 123 Lease liabilities – noncurrent 236 298 Total operating lease liabilities $ 359 $ 421 Weighted average remaining lease term in years 2.83 3.33 Weighted average annual discount rate 10.7 % 10.7 % Maturities of operating lease liabilities as of June 30, 2020, were as follows: 2020 (after June 30) 83 2021 154 2022 135 2023 73 Total undiscounted lease liability 445 Less: Imputed interest (86 ) Present value of lease liabilities $ 359

Share-Based Compensation (Table

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Schedule of employees and directors stock options	Three months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 1,195,563 $ 6.30 1,097,943 $ 6.01 Granted 250,000 $ 3.66 - $ - Forfeited and expired (31,070 ) $ 6.36 (6,292 ) $ 7.23 Exercised (35,895 ) $ 2.69 - $ - Outstanding at end of period 1,378,598 $ 6.15 1,091,651 $ 6.01 Exercisable at end of period 692,032 $ 5.96 553,331 $ 6.03 Non-vested at beginning of the period 482,010 $ 7.20 544,612 $ 6.02 Granted 250,000 $ 3.66 - $ - Vested during the year (14,374 ) $ 3.63 - $ - Forfeited during the year (31,070 ) $ 6.38 (6,292 ) $ 7.23 Non-vested at the end of the period 686,566 $ 5.79 538,320 $ 6.08 Six months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 1,125,927 $ 6.47 1,083,023 $ 4.79 Pre-merger Bioblast options - $ - 15,500 $ 90.16 Granted 320,000 $ 3.89 2,421 $ 12.21 Forfeited and expired (31,434 ) $ 6.39 (8,071 ) $ 0.91 Exercised (35,895 ) $ 2.69 (1,222 ) $ 3.39 Outstanding at end of period 1,378,598 $ 6.15 1,091,651 $ 6.01 Exercisable at end of period 692,032 $ 5.96 553,331 $ 6.03 Non-vested at beginning of the period 425,895 $ 7.21 625,302 $ 5.58 Granted 320,000 $ 3.89 2,421 $ 12.21 Vested during the year (28,259 ) $ 3.09 (81,332 ) $ 3.22 Forfeited during the year (31,070 ) $ 6.37 (8,071 ) $ 0.91 Non-vested at the end of the period 686,566 $ 5.79 538,320 $ 6.08
Schedule of consultants stock options	Three months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 499,115 $ 4.04 718,395 $ 3.72 Outstanding at end of period 499,115 $ 4.04 718,395 $ 3.72 Exercisable at end of period 405,920 $ 3.48 576,183 $ 5.26 Non-vested at beginning of the period 93,194 $ 6.27 142,212 $ 6.29 Vested during the year - $ - - $ - Non-vested at the end of the period 93,194 $ 6.27 142,212 $ 6.29 Six months ended June 30, 2020 2019 Number of options Weighted average exercise price Number of options Weighted average exercise price Outstanding at beginning of period 499,115 $ 4.04 718,395 $ 3.72 Outstanding at end of period 499,115 $ 4.04 718,395 $ 3.72 Exercisable at end of period 405,920 $ 3.48 576,183 $ 5.26 Non-vested at beginning of the period 100,456 $ 6.27 149,474 $ 6.20 Vested during the year (7,262 ) $ 6.22 (7,262 ) $ 6.22 Non-vested at the end of the period 93,194 $ 6.27 142,212 $ 6.29
Schedule of exercise prices and remaining contractual life	Exercise price Number of options outstanding Remaining contractual Life (in years) Intrinsic Value of Options Outstanding No. of options exercisable $ 2.69 688,026 5.02 1,630,623 686,720 $ 3.66 250,000 9.84 349,250 13,889 $ 4.68 66,500 9.76 25,270 - $ 6.22 687,303 7.55 - 377,329 $ 8.19 150,000 9.39 - - $ 10.12 12,943 8.43 - 3,909 $ 12.21 2,421 8.75 - 605 $ 21.40 5,020 9.07 - - $ 90.16 15,500 1.19 - 15,500 1,877,713 $ 2,005,143 1,097,952
Schedule of share-based compensation expenses related to grants under the Equity Incentive Plan	Three months ended Six months ended 2020 2019 2020 2019 Research & development $ 104 $ 31 $ 200 $ 444 General & administrative 84 100 120 199 Total $ 188 $ 131 $ 320 $ 643

Transactions with Related Par_2

Transactions with Related Parties (Tables)	6 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Schedule of Amounts due to the related party	June 30, December 31, 2020 2019 unaudited Accounts payable trade $ 68 $ - Accrued expenses and other 65 79 $ 133 $ 79
Schedule of Amount of transaction with the related party	Three months ended Six months ended 2020 2019 2020 2019 Research and development services $ 160 $ - $ 444 $ -

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value on a recurring basis	June 30, 2020 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 10,163 $ 10,308 $ - $ - Short term deposits 20,043 20,043 - - Cash held with respect to CVR Agreement 2,524 2,524 - - Restricted cash 205 205 - - Total financial assets $ 32,935 $ 32,935 $ - $ - December 31, 2019 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 3,948 $ 3,948 $ - $ - Short term deposits 8,060 8,060 - - Cash held with respect to CVR Agreement 1,400 1,400 - - Restricted cash 176 176 - - Total financial assets $ 13,584 $ 13,584 $ - $ -

General (Details)

General (Details) $ / shares in Units, $ in Thousands	Jun. 30, 2020USD ($)$ / shares	Jun. 30, 2020₪ / shares	Mar. 31, 2020USD ($)$ / sharesshares	Feb. 26, 2020$ / shares	Dec. 31, 2019USD ($)
General (Textual)
Aggregate of ordinary shares | (per share)	$ 10	₪ 0.40	$ 3,093,750	$ 8
Accumulated deficit	$ (29,508)				$ (25,673)
Cash			$ 24,750
Purchase of warrants (in Shares) | shares			2,093,750

Significant Accounting Polici_2

Significant Accounting Policies (Details) - NIS [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Significant Accounting Policies (Details) [Line Items]
Exchange rate for 1 $ = NIS	0.03466		0.03466		0.03456
Increase (decrease) of the U.S. $ against the NIS	(2.80%)	(1.85%)	0.29%	(4.88%)

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash (Details) - Schedule of cash and cash equivalents and restricted cash - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2018
Schedule of cash and cash equivalents and restricted cash [Abstract]
Cash held in banks	$ 655	$ 937
Bank deposits in U.S.$ (annual average interest rates 1.26% and 1.49%)	9,508	3,011
Total cash and cash equivalents	10,163	3,948
Cash held with respect to CVR Agreement	2,524	1,400
Short-term restricted cash	145	100
Long-term restricted cash	60	76
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 12,892	$ 5,524	$ 16,105	$ 9,792

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation expenses	$ 60	$ 92	$ 114	$ 95

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Cost	$ 1,231	$ 1,064
Accumulated depreciation	535	416
Depreciated cost	696	648
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	917	782
Accumulated depreciation	433	340
Computers [Member]
Property, Plant and Equipment [Line Items]
Cost	113	94
Accumulated depreciation	63	51
Office furniture & equipment [Member]
Property, Plant and Equipment [Line Items]
Cost	37	36
Accumulated depreciation	2	1
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Cost	164	152
Accumulated depreciation	$ 37	$ 24

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - Schedule of accrued expenses and other liabilities - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule of accrued expenses and other liabilities [Abstract]
Vacation, convalescence and bonus accruals	$ 253	$ 318
Employees and payroll related	265	274
Short term operating lease liabilities	123	123
Accrued expenses and other	1,320	1,470
Accrued expenses and other liabilities, Total	$ 1,961	$ 2,185

Leases (Details)

Leases (Details)	6 Months Ended
	Jun. 30, 2020
Disclosure Text Block [Abstract]
Operating lease remaining term	3 years 58 days

Leases (Details) - Schedule of

Leases (Details) - Schedule of operating lease - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating leases expenses	$ 93	$ 98
Cash used in operating activities	88	93
Non-cash activity: Right of use assets obtained in exchange for new operating lease liabilities

Leases (Details) - Schedule o_2

Leases (Details) - Schedule of operating lease related activities - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Leases [Abstract]
Other assets - Right-of-Use assets	$ 500	$ 501
Accumulated amortization	158	91
Operating lease Right-of-Use assets, net	342	410
Lease liabilities – current - Accounts payable and accrued liabilities	123	123
Lease liabilities – noncurrent	236	298
Total operating lease liabilities	$ 359	$ 421
Weighted average remaining lease term in years	2 years 302 days	3 years 120 days
Weighted average annual discount rate	10.70%	10.70%
2020 (after June 30)	$ 83
2021	154
2022	135
2023	73
Total undiscounted lease liability	445
Less: Imputed interest	(86)
Present value of lease liabilities	$ 359

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Thousands	1 Months Ended			6 Months Ended
	Jul. 01, 2020	Mar. 31, 2020	Jan. 31, 2020	Jun. 30, 2020	May 15, 2020	Dec. 31, 2019
Commitments and Contingencies (Details) [Line Items]
Percentage of grants				100.00%
Aggregate contingent obligation				$ 5,804
New grant application, description		the Company submitted a grant application to the Israel Innovation Authority for funding of its clinical development program of prevention of organ dysfunction and cytokine storms associated with COVID-19. The Company’s application for grants of NIS 1,857 ($521) representing participation of 30% of the plan to be executed in Israel was approved by the Israel Innovation Authority in April 2020 for a period commencing April 1, 2020 and ending March 31, 2021.	the Company submitted a grant application to the Israel Innovation Authority for funding of its clinical development program of prevention of cytokine storms and organ dysfunction associated with sepsis. The Company’s application for grants of NIS 3,467 ($973) representing participation of 30% of the plan to be executed in Israel was approved by the Israel Innovation Authority in April 2020, for a period commencing January 1, 2020 and ending December 31, 2020.
Agreement, description	the Company entered into a rental agreement for an additional 421 square meters of office and laboratory space, in addition to the 420 square meter rental agreement entered into on July 30, 2018, in the biotechnology park in Ness Ziona. The additional rental agreement is for a period of 63 months, commencing July 1, 2020, and can be extended by an additional period of 35 months. The monthly rental and management fees for the additional space are NIS 28 ($8). To secure the liability of the Company for the new lease, the Company provided the lessor a bank guarantee of approximately NIS 164 ($47).
Common Stock, Value, Issued				$ 1,513		$ 1,151
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Percentage of royalties in sales				3.00%
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Percentage of royalties in sales				5.00%
Ordinary shares [Member] | Financial Investments [Member]
Commitments and Contingencies (Details) [Line Items]
Common Stock, Value, Issued					$ 2,400

Equity (Details)

Equity (Details) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Mar. 05, 2020USD ($)$ / sharesshares	Feb. 26, 2020USD ($)$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020₪ / shares	Mar. 31, 2020$ / shares	Dec. 31, 2019$ / sharesshares	Dec. 31, 2019₪ / sharesshares
Equity (Details) [Line Items]
Ordinary shares | shares	2,093,750	1,000,000	13,463,771			13,463,771	13,463,771
Price per share | (per share)		$ 8	$ 10	₪ 0.40	$ 3,093,750
Net proceeds offering	$ 15,238	$ 7,218
Warrants to purchase shares | shares	2,093,750	70,000	146,563
Exercise price per share | $ / shares		$ 10	$ 10
warrant value		$ 331
Weighted average volatility rate		72.00%
Weighted average risk free interest rate		1.14%
Weighted average contractual expected life		5 years
Ordinary price per share | $ / shares	$ 8
Warrant exercisable | shares	2,093,750
Common stock per share | (per share)	$ 9		$ 0.11	₪ 0.40		$ 0.11	₪ 0.40
Investors warrant			$ 3,723
Common stock value			13,027
Placement agent warrants			$ 232
Warrant [Member]
Equity (Details) [Line Items]
Weighted average volatility rate			68.24%
Weighted average risk free interest rate			0.67%
Weighted average contractual expected life			2 years

Share-Based Compensation (Detai

Share-Based Compensation (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)
Employees' Stock Option [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost	$ 1,750
Weighted average period	1 year 186 days
Consultants' stock options [Member]
Share-Based Compensation (Details) [Line Items]
Total unrecognized estimated compensation cost	$ 199
Weighted average period	1 year 160 days

Share-Based Compensation (Det_2

Share-Based Compensation (Details) - Schedule of employees and directors stock options - Employees’ and directors stock options [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-Based Compensation (Details) - Schedule of employees and directors stock options [Line Items]
Number of options, Outstanding at beginning of period	1,195,563	1,097,943	1,125,927	1,083,023
Weighted average exercise price, Outstanding at beginning of period	$ 6.30	$ 6.01	$ 6.47	$ 4.79
Number of options, Pre-merger Bioblast options				15,500
Weighted average exercise price, Pre-merger Bioblast options				$ 90.16
Number of options, Granted	250,000		320,000	2,421
Weighted average exercise price, Granted	$ 3.66		$ 3.89	$ 12.21
Number of options, Forfeited and expired	(31,070)	(6,292)	(31,434)	(8,071)
Weighted average exercise price, Forfeited and expired	$ 6.36	$ 7.23	$ 6.39	$ 0.91
Number of options, Exercised	(35,895)		(35,895)	(1,222)
Weighted average exercise price, Exercised	$ 2.69		$ 2.69	$ 3.39
Number of options. Outstanding at end of period	1,378,598	1,091,651	1,378,598	1,091,651
Weighted average exercise price, Outstanding at end of period	$ 6.15	$ 6.01	$ 6.15	$ 6.01
Number of options, Exercisable at end of period	692,032	553,331	692,032	553,331
Weighted average exercise price, Exercisable at end of period	$ 5.96	$ 6.03	$ 5.96	$ 6.03
Number of options, Non-vested at beginning of the period	482,010	544,612	425,895	625,302
Weighted average exercise price, Non-vested at beginning of the period	$ 7.20	$ 6.02	$ 7.21	$ 5.58
Number of options, Granted	250,000		320,000	2,421
Weighted average exercise price, Granted	$ 3.66		$ 3.89	$ 12.21
Number of options, Vested during the year	(14,374)		(28,259)	(81,332)
Weighted average exercise price, Vested during the year	$ 3.63		$ 3.09	$ 3.22
Number of options, Forfeited during the year	(31,070)	(6,292)	(31,070)	(8,071)
Weighted average exercise price, Forfeited during the year	$ 6.38	$ 7.23	$ 6.37	$ 0.91
Number of options, Non-vested at the end of the period	686,566	538,320	686,566	538,320
Weighted average exercise price, Non-vested at the end of the period	$ 5.79	$ 6.08	$ 5.79	$ 6.08

Share-Based Compensation (Det_3

Share-Based Compensation (Details) - Schedule of consultants stock options - Consultants' stock options [Member] - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-Based Compensation (Details) - Schedule of consultants stock options [Line Items]
Number of options, Outstanding at beginning of period	499,115	718,395	499,115	718,395
Weighted average exercise price, Outstanding at beginning of period	$ 4.04	$ 3.72	$ 4.04	$ 3.72
Number of options, Outstanding at end of period	499,115	718,395	499,115	718,395
Weighted average exercise price, Outstanding at end of period	$ 4.04	$ 3.72	$ 4.04	$ 3.72
Number of options, Exercisable at end of period	405,920	576,183	405,920	576,183
Weighted average exercise price, Exercisable at end of period	$ 3.48	$ 5.26	$ 3.48	$ 5.26
Number of options, Non-vested at beginning of the period	93,194	142,212	100,456	149,474
Weighted average exercise price, Non-vested at beginning of the period	$ 6.27	$ 6.29	$ 6.27	$ 6.20
Number of options, Vested during the year			(7,262)	(7,262)
Weighted average exercise price, Vested during the year			$ 6.22	$ 6.22
Number of options, Non-vested at the end of the period	93,194	142,212	93,194	142,212
Weighted average exercise price, Non-vested at the end of the period	$ 6.27	$ 6.29	$ 6.27	$ 6.29

Share-Based Compensation (Det_4

Share-Based Compensation (Details) - Schedule of exercise prices and remaining contractual life $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of options outstanding	1,877,713
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 2,005,143
No. of options exercisable	1,097,952
Exercise Price One [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 2.69
Number of options outstanding	688,026
Average Remaining contractual Life (in years)	5 years 7 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 1,630,623
No. of options exercisable	686,720
Exercise Price Two [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 3.66
Number of options outstanding	250,000
Average Remaining contractual Life (in years)	9 years 306 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 349,250
No. of options exercisable	13,889
Exercise Price Three [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 4.68
Number of options outstanding	66,500
Average Remaining contractual Life (in years)	9 years 277 days
Intrinsic Value of Options Outstanding (in Dollars) | $	$ 25,270
No. of options exercisable
Exercise Price Four [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 6.22
Number of options outstanding	687,303
Average Remaining contractual Life (in years)	7 years 200 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	377,329
Exercise Price Five [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 8.19
Number of options outstanding	150,000
Average Remaining contractual Life (in years)	9 years 142 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Six [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 10.12
Number of options outstanding	12,943
Average Remaining contractual Life (in years)	8 years 156 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	3,909
Exercise Price Seven [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 12.21
Number of options outstanding	2,421
Average Remaining contractual Life (in years)	8 years 9 months
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	605
Exercise Price Eight [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 21.40
Number of options outstanding	5,020
Average Remaining contractual Life (in years)	9 years 25 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable
Exercise Price Nine [Member] | Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price (in Dollars per share) | $ / shares	$ 90.16
Number of options outstanding	15,500
Average Remaining contractual Life (in years)	1 year 69 days
Intrinsic Value of Options Outstanding (in Dollars) | $
No. of options exercisable	15,500

Share-Based Compensation (Det_5

Share-Based Compensation (Details) - Schedule of share-based compensation expenses related to grants under the Equity Incentive Plan - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation	$ 188	$ 131	$ 320	$ 643
Research & development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation	104	31	200	444
General & administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based Compensation	$ 84	$ 100	$ 120	$ 199

Transactions with Related Par_3

Transactions with Related Parties (Details) - Schedule of Amounts due to the related party - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Schedule of Amounts due to the related party [Abstract]
Accounts payable trade	$ 68
Accrued expenses and other	65	79
Total	$ 133	$ 79

Transactions with Related Par_4

Transactions with Related Parties (Details) - Schedule of Amount of transaction with the related party - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Schedule of Amount of transaction with the related party [Abstract]
Research and development services	$ 160		$ 444

Fair Value Measurement (Details

Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	$ 10,163	$ 3,948
Short term deposits	20,043	8,060
Cash held with respect to CVR Agreement	2,524	1,400
Restricted cash	205	176
Total financial assets	32,935	13,584
Level 1 [Member]
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents	10,308	3,948
Short term deposits	20,043	8,060
Cash held with respect to CVR Agreement	2,524	1,400
Restricted cash	205	176
Total financial assets	32,935	13,584
Level 2 [Member]
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Cash held with respect to CVR Agreement
Restricted cash
Total financial assets
Level 3 [Member]
Fair Value Measurement (Details) - Schedule of financial assets measured at fair value on a recurring basis [Line Items]
Cash and cash equivalents
Short term deposits
Cash held with respect to CVR Agreement
Restricted cash
Total financial assets